PET imaging for addiction medicine: From neural mechanisms to clinical considerations

Progress in Brain Research

Volumn 224, Issue , 2016, Pages 175-201

  Wiers, Corinde E ^a   Cabrera, Elizabeth ^a   Skarda, Emily ^a   Volkow, Nora D ^a,b   Wang, Gene Jack ^a  

^a NATIONAL INSTITUTE ON ALCOHOL ABUSE AND ALCOHOLISM   (United States)

^b NATIONAL INSTITUTE ON DRUG ABUSE   (United States)

Author keywords

Addiction; Dopamine; Drug dependence; Neuroimaging; Neurotransmission; PET

Indexed keywords

AMINE OXIDASE (FLAVIN CONTAINING); DOPAMINE; DOPAMINE RECEPTOR; ENDOCANNABINOID; FLUORODEOXYGLUCOSE F 18; NICOTINE; NORADRENALIN; OPIATE;

ADDICTION; DOPAMINE METABOLISM; DOPAMINE RELEASE; DOPAMINERGIC TRANSMISSION; EPIGENETICS; GABAERGIC SYSTEM; HUMAN; MULTIMODAL IMAGING; NERVOUS SYSTEM INFLAMMATION; NEUROBIOLOGY; NEUROIMAGING; NEUROTRANSMISSION; NONHUMAN; POSITRON EMISSION TOMOGRAPHY; SEROTONINERGIC SYSTEM; BRAIN; DIAGNOSTIC IMAGING; IMAGE PROCESSING; SUBSTANCE-RELATED DISORDERS;

BRAIN; HUMANS; IMAGE PROCESSING, COMPUTER-ASSISTED; POSITRON-EMISSION TOMOGRAPHY; SUBSTANCE-RELATED DISORDERS;

EID: 84953236955     PISSN: 00796123     EISSN: 18757855     Source Type: Book Series    
DOI: 10.1016/bs.pbr.2015.07.016     Document Type: Chapter

References (108)

1. Albrecht D.S., Skosnik P.D., Vollmer J.M., Brumbaugh M.S., Perry K.M., Mock B.H., et al. Striatal D(2)/D(3) receptor availability is inversely correlated with cannabis consumption in chronic marijuana users. Drug Alcohol Depend. 2013, 128(1-2):52-57. 10.1016/J.Drugalcdep.2012.07.016.
2. Bacher I., Houle S., Xu X., Zawertailo L., Soliman A., Wilson A.A., et al. Monoamine oxidase a binding in the prefrontal and anterior cingulate cortices during acute withdrawal from heavy cigarette smoking. Arch. Gen. Psychiatry 2011, 68(8):817-826. 10.1001/Archgenpsychiatry.2011.82.
3. Ballard M.E., Mandelkern M.A., Monterosso J.R., Hsu E., Robertson C.L., Ishibashi K., et al. Low dopamine D2/D3 receptor availability is associated with steep discounting of delayed rewards in methamphetamine dependence. Int. J. Neuropsychopharmacol. 2015, 18(7):pyu119. 10.1093/Ijnp/Pyu119.
4. Benveniste H., Fowler J.S., Rooney W.D., Scharf B.A., Backus W.W., Izrailtyan I., et al. Cocaine is pharmacologically active in the nonhuman primate fetal brain. Proc. Natl. Acad. Sci. U. S. A. 2010, 107(4):1582-1587. 10.1073/Pnas.0909585107.
5. Berridge M.S., Apana S.M., Nagano K.K., Berridge C.E., Leisure G.P., Boswell M.V. Smoking produces rapid rise of [11C]nicotine in human brain. Psychopharmacology (Berl.) 2010, 209(4):383-394. 10.1007/S00213-010-1809-8.
6. Bloomfield M.A., Morgan C.J., Egerton A., Kapur S., Curran H.V., Howes O.D. Dopaminergic function in cannabis users and its relationship to cannabis-induced psychotic symptoms. Biol. Psychiatry 2014, 75(6):470-478. 10.1016/J.Biopsych.2013.05.027.
7. Bloomfield M.A., Morgan C.J., Kapur S., Curran H.V., Howes O.D. The link between dopamine function and apathy in cannabis users: an [18F]-DOPA PET imaging study. Psychopharmacology (Berl.) 2014, 231(11):2251-2259. 10.1007/S00213-014-3523-4.
8. Bloomfield M.A., Pepper F., Egerton A., Demjaha A., Tomasi G., Mouchlianitis E., et al. Dopamine function in cigarette smokers: an [(1)(8)F]-DOPA PET study. Neuropsychopharmacology 2014, 39(10):2397-2404. 10.1038/Npp.2014.87.
9. Boileau I., Payer D., Houle S., Behzadi A., Rusjan P.M., Tong J., et al. Higher binding of the dopamine D3 receptor-preferring ligand [11C]-(+)-propyl-hexahydro-naphtho-oxazin in methamphetamine polydrug users: a positron emission tomography study. J. Neurosci. 2012, 32(4):1353-1359. 10.1523/Jneurosci.4371-11.2012.
10. Brody A.L., London E.D., Olmstead R.E., Allen-Martinez Z., Shulenberger S., Costello M.R., et al. Smoking-induced change in intrasynaptic dopamine concentration: effect of treatment for tobacco dependence. Psychiatry Res. 2010, 183(3):218-224. 10.1016/J.Pscychresns.2009.06.004.
11. Brody A.L., Mandelkern M.A., London E.D., Khan A., Kozman D., Costello M.R., et al. Effect of secondhand smoke on occupancy of nicotinic acetylcholine receptors in brain. Arch. Gen. Psychiatry 2011, 68(9):953-960. 10.1001/Archgenpsychiatry.2011.51.
12. Brody A.L., Mukhin A.G., La Charite J., Ta K., Farahi J., Sugar C.A., et al. Up-regulation of nicotinic acetylcholine receptors in menthol cigarette smokers. Int. J. Neuropsychopharmacol. 2013, 16(5):957-966. 10.1017/S1461145712001022.
13. Brody A.L., Mukhin A.G., Mamoun M.S., Luu T., Neary M., Liang L., et al. Brain nicotinic acetylcholine receptor availability and response to smoking cessation treatment: a randomized trial. JAMA Psychiatry 2014, 71(7):797-805. 10.1001/Jamapsychiatry.2014.138.
14. Brown A.K., George D.T., Fujita M., Liow J.S., Ichise M., Hibbeln J., et al. Pet [11C]DASB imaging of serotonin transporters in patients with alcoholism. Alcohol. Clin. Exp. Res. 2007, 31(1):28-32. 10.1111/J.1530-0277.2006.00261.X.
15. Ceccarini J., Hompes T., Verhaeghen A., Casteels C., Peuskens H., Bormans G., et al. Changes in cerebral CB1 receptor availability after acute and chronic alcohol abuse and monitored abstinence. J. Neurosci. 2014, 34(8):2822-2831. 10.1523/Jneurosci.0849-13.2014.
16. Ceccarini J., Kuepper R., Kemels D., Van Os J., Henquet C., Van Laere K. [(18)F]MK-9470 PET measurement of cannabinoid CB1 receptor availability in chronic cannabis users. Addict. Biol. 2015, 20(2):357-367. 10.1111/Adb.12116.
17. Colasanti A., Searle G.E., Long C.J., Hill S.P., Reiley R.R., Quelch D., et al. Endogenous opioid release in the human brain reward system induced by acute amphetamine administration. Biol. Psychiatry 2012, 72(5):371-377. 10.1016/J.Biopsych.2012.01.027.
18. Costello M.R., Mandelkern M.A., Shoptaw S., Shulenberger S., Baker S.K., Abrams A.L., et al. Effects of treatment for tobacco dependence on resting cerebral glucose metabolism. Neuropsychopharmacology 2010, 35(3):605-612. 10.1038/Npp.2009.165.
19. Deserno L., Beck A., Huys Q.J., Lorenz R.C., Buchert R., Buchholz H.G., et al. Chronic alcohol intake abolishes the relationship between dopamine synthesis capacity and learning signals in the ventral striatum. Eur. J. Neurosci. 2014, 41(4):477-486. 10.1111/Ejn.12802.
20. Ding Y.S., Singhal T., Planeta-Wilson B., Gallezot J.D., Nabulsi N., Labaree D., et al. PET imaging of the effects of age and cocaine on the norepinephrine transporter in the human brain using (S, S)-[(11)C]O-methylreboxetine and HRRT. Synapse 2010, 64(1):30-38. 10.1002/Syn.20696.
21. Erritzoe D., Tziortzi A., Bargiela D., Colasanti A., Searle G.E., Gunn R.N., et al. In vivo imaging of cerebral dopamine D3 receptors in alcoholism. Neuropsychopharmacology 2014, 39(7):1703-1712. 10.1038/Npp.2014.18.
22. Foll B.L., Payer D., Ciano P.D., Guranda M., Nakajima S., Tong J., et al. Occupancy of dopamine D and D receptors by buspirone: a [C]-(+)-PHNO PET study in humans. Neuropsychopharmacology 2015, Epub ahead of print. 10.1038/Npp.2015.177.
23. Fotros A., Casey K.F., Larcher K., Verhaeghe J.A., Cox S.M., Gravel P., et al. Cocaine cue-induced dopamine release in amygdala and hippocampus: a high-resolution PET [(1)(8)F]fallypride study in cocaine dependent participants. Neuropsychopharmacology 2013, 38(9):1780-1788. 10.1038/Npp.2013.77.
24. Fowler J.S., Logan J., Shumay E., Alia-Klein N., Wang G.J., Volkow N.D. Monoamine oxidase: radiotracer chemistry and human studies. J. Labelled. Comp. Radiopharm. 2015, 58(3):51-64. 10.1002/Jlcr.3247.
25. Ghitza U.E., Preston K.L., Epstein D.H., Kuwabara H., Endres C.J., Bencherif B., et al. Brain mu-opioid receptor binding predicts treatment outcome in cocaine-abusing outpatients. Biol. Psychiatry 2010, 68(8):697-703. 10.1016/J.Biopsych.2010.05.003.
26. Gorelick D.A., Kim Y.K., Bencherif B., Boyd S.J., Nelson R., Copersino M., et al. Imaging brain mu-opioid receptors in abstinent cocaine users: time course and relation to cocaine craving. Biol. Psychiatry 2005, 57(12):1573-1582. 10.1016/J.Biopsych.2005.02.026.
27. Gorelick D.A., Kim Y.K., Bencherif B., Boyd S.J., Nelson R., Copersino M.L., et al. Brain mu-opioid receptor binding: relationship to relapse to cocaine use after monitored abstinence. Psychopharmacology (Berl.) 2008, 200(4):475-486. 10.1007/S00213-008-1225-5.
28. Guterstam J., Jayaram-Lindstrom N., Cervenka S., Frost J.J., Farde L., Halldin C., Franck J. Effects of amphetamine on the human brain opioid system-a positron emission tomography study. Int. J. Neuropsychopharmacol. 2013, 16(4):763-769. 10.1017/S1461145712000818.
29. Haile C.N., Mahoney J.J., Newton T.F., De La Garza R. Pharmacotherapeutics directed at deficiencies associated with cocaine dependence: focus on dopamine, norepinephrine and glutamate. Pharmacol. Ther. 2012, 134(2):260-277. 10.1016/J.Pharmthera.2012.01.010.
30. Heinz A., Siessmeier T., Wrase J., Buchholz H.G., Grunder G., Kumakura Y., et al. Correlation of alcohol craving with striatal dopamine synthesis capacity and D2/3 receptor availability: a combined [18F]DOPA and [18F]DMFP PET study in detoxified alcoholic patients. Am. J. Psychiatry 2005, 162(8):1515-1520. 10.1176/Appi.Ajp.162.8.1515.
31. Henry P.K., Murnane K.S., Votaw J.R., Howell L.L. Acute brain metabolic effects of cocaine in rhesus monkeys with a history of cocaine use. Brain Imaging Behav. 2010, 4(3-4):212-219. 10.1007/S11682-010-9100-5.
32. Hirvonen J., Goodwin R.S., Li C.T., Terry G.E., Zoghbi S.S., Morse C., et al. Reversible and regionally selective downregulation of brain cannabinoid CB1 receptors in chronic daily cannabis smokers. Mol. Psychiatry 2012, 17(6):642-649. 10.1038/Mp.2011.82.
33. Hirvonen J., Zanotti-Fregonara P., Umhau J.C., George D.T., Rallis-Frutos D., Lyoo C.H., et al. Reduced cannabinoid CB1 receptor binding in alcohol dependence measured with positron emission tomography. Mol. Psychiatry 2013, 18(8):916-921. 10.1038/Mp.2012.100.
34. Horti A.G., Kuwabara H., Holt D.P., Dannals R.F., Wong D.F. Recent PET radioligands with optimal brain kinetics for imaging nicotinic acetylcholine receptors. J. Labelled. Comp. Radiopharm. 2013, 56(3-4):159-166. 10.1002/Jlcr.3020.
35. Hou H., Wang C., Jia S., Hu S., Tian M. Brain dopaminergic system changes in drug addiction: a review of positron emission tomography findings. Neurosci. Bull. 2014, 30(5):765-776. 10.1007/S12264-014-1469-5.
36. Hu J., Henry S., Gallezot J.D., Ropchan J., Neumaier J.F., Potenza M.N., et al. Serotonin 1B receptor imaging in alcohol dependence. Biol. Psychiatry 2010, 67(9):800-803. 10.1016/J.Biopsych.2009.12.028.
37. Hulka L.M., Treyer V., Scheidegger M., Preller K.H., Vonmoos M., Baumgartner M.R., et al. Smoking but not cocaine use is associated with lower cerebral metabotropic glutamate receptor 5 density in humans. Mol. Psychiatry 2014, 19(5):625-632. 10.1038/Mp.2013.51.
38. Jones T., Rabiner E.A., PET Research Advisory Company The development, past achievements, and future directions of brain PET. J. Cereb. Blood Flow Metab. 2012, 32(7):1426-1454. 10.1038/Jcbfm.2012.20.
39. Kienast T., Schlagenhauf F., Rapp M.A., Wrase J., Daig I., Buchholz H.G., et al. Dopamine-modulated aversive emotion processing fails in alcohol-dependent patients. Pharmacopsychiatry 2013, 46(4):130-136. 10.1055/S-0032-1331747.
40. Kim S.W., Hooker J.M., Otto N., Win K., Muench L., Shea C., et al. Whole-body pharmacokinetics of HDAC inhibitor drugs, butyric acid, valproic acid and 4-phenylbutyric acid measured with carbon-11 labeled analogs by PET. Nucl. Med. Biol. 2013, 40(7):912-918. 10.1016/J.Nucmedbio.2013.06.007.
41. Kim S.W., Fowler J.S., Skolnick P., Muench L., Kang Y., Shea C., et al. Therapeutic doses of buspirone block D3 receptors in the living primate brain. Int. J. Neuropsychopharmacol. 2014, 17(8):1257-1267. 10.1017/S1461145714000194.
42. Koob G.F., Le Moal M. Review. Neurobiological mechanisms for opponent motivational processes in addiction. Philos. Trans. R. Soc. Lond. B Biol. Sci. 2008, 363(1507):3113-3123. 10.1098/Rstb.2008.0094.
43. Koob G.F., Volkow N.D. Neurocircuitry of addiction. Neuropsychopharmacology 2010, 35(1):217-238. 10.1038/Npp.2009.110.
44. Kreisl W.C., Lyoo C.H., Mcgwier M., Snow J., Jenko K.J., Kimura N., et al. In vivo radioligand binding to translocator protein correlates with severity of Alzheimer's disease. Brain 2013, 136(Pt. 7):2228-2238. 10.1093/Brain/Awt145.
45. Kumakura Y., Gjedde A., Caprioli D., Kienast T., Beck A., Plotkin M., et al. Increased turnover of dopamine in caudate nucleus of detoxified alcoholic patients. PLoS ONE 2013, 8(9):E73903. 10.1371/Journal.Pone.0073903.
46. Kuwabara H., Heishman S.J., Brasic J.R., Contoreggi C., Cascella N., Mackowick K.M., et al. Mu opioid receptor binding correlates with nicotine dependence and reward in smokers. PLoS ONE 2014, 9(12):E113694. 10.1371/Journal.Pone.0113694.
47. Landau A.M., Doudet D.J., Jakobsen S. Amphetamine challenge decreases yohimbine binding to alpha2 adrenoceptors in landrace pig brain. Psychopharmacology (Berl.) 2012, 222(1):155-163. 10.1007/S00213-011-2632-6.
48. Lee B., London E.D., Poldrack R.A., Farahi J., Nacca A., Monterosso J.R., et al. Striatal dopamine D2/D3 receptor availability is reduced in methamphetamine dependence and is linked to impulsivity. J. Neurosci. 2009, 29(47):14734-14740. 10.1523/Jneurosci.3765-09.2009.
49. Leroy C., Karila L., Martinot J.L., Lukasiewicz M., Duchesnay E., Comtat C., et al. Striatal and extrastriatal dopamine transporter in cannabis and tobacco addiction: a high-resolution PET study. Addict. Biol. 2012, 17(6):981-990. 10.1111/J.1369-1600.2011.00356.X.
50. Lingford-Hughes A., Reid A.G., Myers J., Feeney A., Hammers A., Taylor L.G., et al. A [11C]RO15 4513 PET study suggests that alcohol dependence in man is associated with reduced alpha5 benzodiazepine receptors in limbic regions. J. Psychopharmacol. 2012, 26(2):273-281. 10.1177/0269881110379509.
51. Logan J., Volkow N.D., Fowler J.S., Wang G.J., Fischman M.W., Foltin R.W., et al. Concentration and occupancy of dopamine transporters in cocaine abusers with [11C]cocaine and PET. Synapse 1997, 27(4):347-356. 10.1002/(Sici)1098-2396(199712)27:4<347::Aid-Syn8>3.0.Co;2-C.
52. London E.D., Kohno M., Morales A.M., Ballard M.E. Chronic methamphetamine abuse and corticostriatal deficits revealed by neuroimaging. Brain Res. 2014, Epub ahead of print. 10.1016/J.Brainres.2014.10.044.
53. Luo S.X., Martinez D., Carpenter K.M., Slifstein M., Nunes E.V. Multimodal predictive modeling of individual treatment outcome in cocaine dependence with combined neuroimaging and behavioral predictors. Drug Alcohol Depend. 2014, 143:29-35. 10.1016/J.Drugalcdep.2014.04.030.
54. Maoz A., Hicks M.J., Vallabhjosula S., Synan M., Kothari P.J., Dyke J.P., et al. Adenovirus capsid-based anti-cocaine vaccine prevents cocaine from binding to the nonhuman primate CNS dopamine transporter. Neuropsychopharmacology 2013, 38(11):2170-2178. 10.1038/Npp.2013.114.
55. Martinez D., Gil R., Slifstein M., Hwang D.R., Huang Y., Perez A., et al. Alcohol dependence is associated with blunted dopamine transmission in the ventral striatum. Biol. Psychiatry 2005, 58(10):779-786. 10.1016/J.Biopsych.2005.04.044.
56. Martinez D., Slifstein M., Narendran R., Foltin R.W., Broft A., Hwang D.R., et al. Dopamine D1 receptors in cocaine dependence measured with PET and the choice to self-administer cocaine. Neuropsychopharmacology 2009, 34(7):1774-1782. 10.1038/Npp.2008.235.
57. Martinez D., Carpenter K.M., Liu F., Slifstein M., Broft A., Friedman A.C., et al. Imaging dopamine transmission in cocaine dependence: link between neurochemistry and response to treatment. Am. J. Psychiatry 2011, 168(6):634-641. 10.1176/Appi.Ajp.2010.10050748.
58. Matthews B.A., Kish S.J., Xu X., Boileau I., Rusjan P.M., Wilson A.A., et al. Greater monoamine oxidase a binding in alcohol dependence. Biol. Psychiatry 2014, 75(10):756-764. 10.1016/J.Biopsych.2013.10.010.
59. Matuskey D., Bhagwagar Z., Planeta B., Pittman B., Gallezot J.D., Chen J., et al. Reductions in brain 5-HT1B receptor availability in primarily cocaine-dependent humans. Biol. Psychiatry 2014, 76(10):816-822. 10.1016/J.Biopsych.2013.11.022.
60. Matuskey D., Gallezot J.D., Pittman B., Williams W., Wanyiri J., Gaiser E., et al. Dopamine D(3) receptor alterations in cocaine-dependent humans imaged with [(1)(1)C](+)PHNO. Drug Alcohol Depend. 2014, 139:100-105. 10.1016/J.Drugalcdep.2014.03.013.
61. Mayfield J., Ferguson L., Harris R.A. Neuroimmune signaling: a key component of alcohol abuse. Curr. Opin. Neurobiol. 2013, 23(4):513-520. 10.1016/J.Conb.2013.01.024.
62. Michaelides M., Thanos P.K., Kim R., Cho J., Ananth M., Wang G.J., Volkow N.D. PET imaging predicts future body weight and cocaine preference. Neuroimage 2012, 59(2):1508-1513. 10.1016/J.Neuroimage.2011.08.028.
63. Minkowski C.P., Epstein D., Frost J.J., Gorelick D.A. Differential response to Iv carfentanil in chronic cocaine users and healthy controls. Addict. Biol. 2012, 17(1):149-155. 10.1111/J.1369-1600.2010.00256.X.
64. Muzic R.F., Berridge M.S., Friedland R.P., Zhu N., Nelson A.D. PET quantification of specific binding of carbon-11-nicotine in human brain. J. Nucl. Med. 1998, 39(12):2048-2054.
65. Narendran R., Lopresti B.J., Martinez D., Mason N.S., Himes M., May M.A., et al. In vivo evidence for low striatal vesicular monoamine transporter 2 (VMAT2) availability in cocaine abusers. Am. J. Psychiatry 2012, 169(1):55-63. 10.1176/Appi.Ajp.2011.11010126.
66. Narendran R., Lopresti B.J., Mason N.S., Deuitch L., Paris J., Himes M.L., et al. Cocaine abuse in humans is Not associated with increased microglial activation: an 18-kDa translocator protein positron emission tomography imaging study with [11C]PBR28. J. Neurosci. 2014, 34(30):9945-9950. 10.1523/Jneurosci.0928-14.2014.
67. Neumeister A., Normandin M.D., Murrough J.W., Henry S., Bailey C.R., Luckenbaugh D.A., et al. Positron emission tomography shows elevated cannabinoid CB1 receptor binding in men with alcohol dependence. Alcohol. Clin. Exp. Res. 2012, 36(12):2104-2109. 10.1111/J.1530-0277.2012.01815.X.
68. Nutt D.J., Besson M., Wilson S.J., Dawson G.R., Lingford-Hughes A.R. Blockade of alcohol's amnestic activity in humans by an alpha5 subtype benzodiazepine receptor inverse agonist. Neuropharmacology 2007, 53(7):810-820. 10.1016/J.Neuropharm.2007.08.008.
69. Oberlin B.G., Dzemidzic M., Tran S.M., Soeurt C.M., Albrecht D.S., Yoder K.K., Kareken D.A. Beer flavor provokes striatal dopamine release in male drinkers: mediation by family history of alcoholism. Neuropsychopharmacology 2013, 38(9):1617-1624. 10.1038/Npp.2013.91.
70. Park K., Volkow N.D., Pan Y., Du C. Chronic cocaine dampens dopamine signaling during cocaine intoxication and unbalances D1 over D2 receptor signaling. J. Neurosci. 2013, 33(40):15827-15836. 10.1523/Jneurosci.1935-13.2013.
71. Payer D.E., Behzadi A., Kish S.J., Houle S., Wilson A.A., Rusjan P.M., et al. Heightened D3 dopamine receptor levels in cocaine dependence and contributions to the addiction behavioral phenotype: a positron emission tomography study with [11C]-+-PHNO. Neuropsychopharmacology 2014, 39(2):311-318. 10.1038/Npp.2013.192.
72. Ray R., Ruparel K., Newberg A., Wileyto E.P., Loughead J.W., Divgi C., et al. Human mu opioid receptor (OPRM1 A118G) polymorphism is associated with brain mu-opioid receptor binding potential in smokers. Proc. Natl. Acad. Sci. U. S. A. 2011, 108(22):9268-9273. 10.1073/Pnas.1018699108.
73. Rominger A., Cumming P., Xiong G., Koller G., Boning G., Wulff M., et al. [18F]fallypride PET measurement of striatal and extrastriatal dopamine D 2/3 receptor availability in recently abstinent alcoholics. Addict. Biol. 2012, 17(2):490-503. 10.1111/J.1369-1600.2011.00355.X.
74. Schneider N.G., Lunell E., Olmstead R.E., Fagerstrom K.O. Clinical pharmacokinetics of nasal nicotine delivery. A review and comparison to other nicotine systems. Clin. Pharmacokinet. 1996, 31(1):65-80. 10.2165/00003088-199631010-00005.
75. Schultz W. Dopamine signals for reward value and risk: basic and recent data. Behav. Brain Funct. 2010, 6:24. 10.1186/1744-9081-6-24.
76. Sekine Y., Ouchi Y., Sugihara G., Takei N., Yoshikawa E., Nakamura K., et al. Methamphetamine causes microglial activation in the brains of human abusers. J. Neurosci. 2008, 28(22):5756-5761. 10.1523/Jneurosci.1179-08.2008.
77. Shumay E., Logan J., Volkow N.D., Fowler J.S. Evidence that the methylation state of the monoamine oxidase a (maoa) gene predicts brain activity of Mao a enzyme in healthy men. Epigenetics 2012, 7(10):1151-1160. 10.4161/Epi.21976.
78. Sofuoglu M., Sewell R.A. Norepinephrine and stimulant addiction. Addict. Biol. 2009, 14(2):119-129. 10.1111/J.1369-1600.2008.00138.X.
79. Stokes P.R.A., Egerton A., Watson B., Reid A., Lappin J., Howes O.D., et al. History of cannabis use is not associated with alterations in striatal dopamine D-2/D-3 receptor availability. J. Psychopharmacol. 2012, 26(1):144-149. 10.1177/0269881111414090.
80. Stokes P.R.A., Benecke A., Myers J., Erritzoe D., Watson B.J., Kalk N., et al. History of cigarette smoking is associated with higher limbic gabaa receptor availability. Neuroimage 2013, 69:70-77. 10.1016/J.Neuroimage.2012.12.010.
81. Szabo Z., Owonikoko T., Peyrot M., Varga J., Mathews W.B., Ravert H.T., et al. Positron emission tomography imaging of the serotonin transporter in subjects with a history of alcoholism. Biol. Psychiatry 2004, 55(7):766-771. 10.1016/J.Biopsych.2003.11.023.
82. Thanos P.K., Wang G.J., Volkow N.D. Positron emission tomography as a tool for studying alcohol abuse. Alcohol Res. Health 2008, 31(3):233-237.
83. Tomasi D., Wang G.J., Wang R., Caparelli E.C., Logan J., Volkow N.D. Overlapping patterns of brain activation to food and cocaine cues in cocaine abusers: association to striatal D2/D3 receptors. Hum. Brain Mapp. 2015, 36(1):120-136. 10.1002/Hbm.22617.
84. Trifilieff P., Martinez D. Imaging addiction: D2 receptors and dopamine signaling in the striatum as biomarkers for impulsivity. Neuropharmacology 2014, 76(Pt. B):498-509. 10.1016/J.Neuropharm.2013.06.031.
85. Urban N.B., Slifstein M., Thompson J.L., Xu X., Girgis R.R., Raheja S., et al. Dopamine release in chronic cannabis users: a [11C]raclopride positron emission tomography study. Biol. Psychiatry 2012, 71(8):677-683. 10.1016/J.Biopsych.2011.12.018.
86. Van Amsterdam J., Talhout R., Vleeming W., Opperhuizen A. Contribution of monoamine oxidase (MAO) inhibition to tobacco and alcohol addiction. Life Sci. 2006, 79(21):1969-1973. 10.1016/J.Lfs.2006.06.010.
87. Volkow N.D., Baler R.D. Addiction science: uncovering neurobiological complexity. Neuropharmacology 2014, 76pb:235-249. 10.1016/J.Neuropharm.2013.05.007.
88. Volkow N.D., Wang G.J., Fowler J.S., Logan J., Hitzemann R., Ding Y.S., et al. Decreases in dopamine receptors but not in dopamine transporters in alcoholics. Alcohol. Clin. Exp. Res. 1996, 20(9):1594-1598.
89. Volkow N.D., Wang G.J., Begleiter H., Porjesz B., Fowler J.S., Telang F., et al. High levels of dopamine D2 receptors in unaffected members of alcoholic families: possible protective factors. Arch. Gen. Psychiatry 2006, 63(9):999-1008. 10.1001/Archpsyc.63.9.999.
90. Volkow N.D., Wang G.J., Telang F., Fowler J.S., Logan J., Jayne M., et al. Profound decreases in dopamine release in striatum in detoxified alcoholics: possible orbitofrontal involvement. J. Neurosci. 2007, 27(46):12700-12706. 10.1523/Jneurosci.3371-07.2007.
91. Volkow N.D., Fowler J.S., Wang G.J., Baler R., Telang F. Imaging Dopamine's role in drug abuse and addiction. Neuropharmacology 2009, 56(Suppl. 1):3-8. 10.1016/J.Neuropharm.2008.05.022.
92. Volkow N.D., Fowler J.S., Wang G.J., Telang F., Logan J., Jayne M., et al. Cognitive control of drug craving inhibits brain reward regions in cocaine abusers. Neuroimage 2010, 49(3):2536-2543. 10.1016/J.Neuroimage.2009.10.088.
93. Volkow N.D., Wang G.J., Tomasi D., Telang F., Fowler J.S., Pradhan K., et al. Methylphenidate attenuates limbic brain inhibition after cocaine-cues exposure in cocaine abusers. PLoS ONE 2010, 5(7):E11509. 10.1371/Journal.Pone.0011509.
94. Volkow N.D., Tomasi D., Wang G.J., Fowler J.S., Telang F., Goldstein R.Z., et al. Reduced metabolism in brain "control networks" following cocaine-cues exposure in female cocaine abusers. PLoS ONE 2011, 6(2):E16573. 10.1371/Journal.Pone.0016573.
95. Volkow N.D., Wang G.J., Fowler J.S., Tomasi D., Telang F. Addiction: beyond dopamine reward circuitry. Proc. Natl. Acad. Sci. U. S. A. 2011, 108(37):15037-15042. 10.1073/Pnas.1010654108.
96. Volkow N.D., Wang G.J., Fowler J.S., Tomasi D. Addiction circuitry in the human brain. Annu. Rev. Pharmacol. Toxicol. 2012, 52:321-336. 10.1146/Annurev-Pharmtox-010611-134625.
97. Volkow N.D., Kim S.W., Wang G.J., Alexoff D., Logan J., Muench L., et al. Acute alcohol intoxication decreases glucose metabolism but increases acetate uptake in the human brain. Neuroimage 2013, 64:277-283. 10.1016/J.Neuroimage.2012.08.057.
98. Volkow N.D., Tomasi D., Wang G.J., Telang F., Fowler J.S., Goldstein R.Z., et al. Association between dopamine D4 receptor polymorphism and age related changes in brain glucose metabolism. PLoS ONE 2013, 8(5):E63492. 10.1371/Journal.Pone.0063492.
99. Volkow N.D., Tomasi D., Wang G.J., Telang F., Fowler J.S., Logan J., et al. Predominance of D2 receptors in mediating Dopamine's effects in brain metabolism: effects of alcoholism. J. Neurosci. 2013, 33(10):4527-4535. 10.1523/Jneurosci.5261-12.2013.
100. Volkow N.D., Tomasi D., Wang G.J., Logan J., Alexoff D.L., Jayne M., et al. Stimulant-induced dopamine increases are markedly blunted in active cocaine abusers. Mol. Psychiatry 2014, 19(9):1037-1043. 10.1038/Mp.2014.58.
101. Volkow N.D., Wang G.J., Telang F., Fowler J.S., Alexoff D., Logan J., et al. Decreased dopamine brain reactivity in marijuana abusers is associated with negative emotionality and addiction severity. Proc. Natl. Acad. Sci. U. S. A. 2014, 111(30):E3149-E3156. 10.1073/Pnas.1411228111.
102. Volkow N.D., Wang G.J., Shokri Kojori E., Fowler J.S., Benveniste H., Tomasi D. Alcohol decreases baseline brain glucose metabolism more in heavy drinkers than controls but has no effect on stimulation-induced metabolic increases. J. Neurosci. 2015, 35(7):3248-3255. 10.1523/Jneurosci.4877-14.2015.
103. Wang G.J., Smith L., Volkow N.D., Telang F., Logan J., Tomasi D., et al. Decreased dopamine activity predicts relapse in methamphetamine abusers. Mol. Psychiatry 2012, 17(9):918-925. 10.1038/Mp.2011.86.
104. Wang C., Schroeder F.A., Wey H.Y., Borra R., Wagner F.F., Reis S., et al. In vivo imaging of histone deacetylases (HDACs) in the central nervous system and major peripheral organs. J. Med. Chem. 2014, 57(19):7999-8009. 10.1021/Jm500872p.
105. Weerts E.M., Wand G.S., Kuwabara H., Munro C.A., Dannals R.F., Hilton J., et al. Positron emission tomography imaging of mu- and delta-opioid receptor binding in alcohol-dependent and healthy control subjects. Alcohol. Clin. Exp. Res. 2011, 35(12):2162-2173. 10.1111/J.1530-0277.2011.01565.X.
106. Weerts E.M., Wand G.S., Kuwabara H., Xu X., Frost J.J., Wong D.F., Mccaul M.E. Association of smoking with mu-opioid receptor availability before and during naltrexone blockade in alcohol-dependent subjects. Addict. Biol. 2014, 19(4):733-742. 10.1111/Adb.12022.
107. Winhusen T.M., Kropp F., Lindblad R., Douaihy A., Haynes L., Hodgkins C., et al. Multisite, randomized, double-blind, placebo-controlled pilot clinical trial to evaluate the efficacy of buspirone as a relapse-prevention treatment for cocaine dependence. J. Clin. Psychiatry 2014, 75(7):757-764. 10.4088/Jcp.13m08862.
108. Zuo Y., Mukhin A.G., Garg S., Nazih R., Behm F.M., Garg P.K., Rose J.E. Sex-specific effects of cigarette mentholation on brain nicotine accumulation and smoking behavior. Neuropsychopharmacology 2015, 40(4):884-892. 10.1038/Npp.2014.263.